Page 30 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

Author, Year Mean N Duration Disease Results Quality
Age (weeks) Severity Rating
(years)
Mohs et al. 2001 42 75 431 54 Mild- Significantly fewer people on DON than Fair
moderate on placebo had clinically significant
functional loss
Rogers et al., 1996 45 72 161 12 Mild - Symptoms: significantly better cognitive Fair
moderate and global assessment scores for DON
Behavior / function: no significant
differences in QoL and activities of
daily living
Rogers et al., 1998 44 73 473 24 Mild - Symptoms: significantly better cognitive Fair
moderate and global assessment scores for DON
Behavior / function: QoL scores
significantly better with DON 5mg but
not DON 10 mg
Rogers et al., 1998 43 74 468 12 Mild - Symptoms: significantly better cognitive Fair
moderate and global assessment scores for DON
Behavior / function: QoL scores
significantly better with DON 10mg but
not DON 5 mg
Seltzer et al. 2004 46 74 157 24 Mild Symptoms: significantly better cognitive Fair
and global assessment scores for DON
Behavior / function: NR
Tariot et al., 2001 47 86 208 20 Mild - Symptoms: significantly better cognitive Fair
moderate and global assessment scores for DON
Behavior / function: NR
Winblad et al., 73 286 52 Mild - Symptoms: significantly slower decline in Fair
48
2001 moderate cognitive and global assessment
scores for DON
Behavior / function: no difference in
behavior and functional capacity
Galantamine vs. Placebo
Loy & Schneider, NR 3,77 >4 NR Symptoms: significantly slower decline in Good
2005 (SR) 34, 62 7 cognitive and global assessment
scores for GAL 16-32mg/d
Behavior / function: Mixed evidence for
behavior and function; most trials
reported statistically significant
differences only at higher doses
Brodaty et al., 77 971 26 Mild - Symptoms: significantly slower decline in Good
49
2005 moderate cognitive and global assessment
scores for GAL and GAL PRC
Behavior / function: significantly better
function scores for GAL and GAL PRC
but no differences in behavior
Raskind et al., 75 636 26 Mild - Symptoms: significantly slower decline in Fair
50
2000 moderate cognitive and global assessment
scores for GAL
Behavior / function: No significant
difference in function
Rockwood et al., 75 386 26 Mild - Symptoms: significantly slower decline in Fair
2001 51, 63 moderate cognitive and global assessment
scores for GAL
Behavior / function: significantly slower
decline in function for GAL; no
difference in behavior or sleep

Alzheimer's Drugs Page 30 of 205